ガイドライン

(旧版)大腸癌治療ガイドライン医師用 2010年版

<前へ 次へ>
書誌情報
文 献



1) Kudo S: Endoscopic mucosal resection of flat and depressed early colorectal cancer. Endoscopy 1993; 25: 455-461
2) 井上晴洋,竹下公矢,遠藤光夫,他:早期胃癌に対する内視鏡的粘膜切除術―透明プラスチックキャップを用いる方法(EMRC)―.Gastroenterol Endosc 1993; 35: 600-607
3) Tanaka S, Oka S, Chayama K: Colorectal endoscopic submucosal dissection(ESD): the present status and future perspective including its differentiation from endoscopic mucosal resection(EMR). J Gastroenterol 2008; 43: 641-651
4) Saitoh Y, Obara T, Watari J, et al: Invasion depth diagnosis of depressed type early colorectal cancers by combined use of videoendoscopy and chromoendoscopy. Gastrointest Endosc 1998; 48: 362-370
5) Watari J, Saitoh Y, Obara T, et al: Early nonpolypoid colorectal cancer: radiographic diagnosis of depth of invasion. Radiology 1997; 205: 67-74
6) Tanaka S, Kaltenbach T, Chayama K, et al: High-magnification colonoscopy. Gastrointest Endosc 2006; 64: 604-613
7) 浜本順博,平田一郎,安本真悟,他:早期大腸癌における浸潤度の臨床診断精度―超音波内視鏡を中心に.胃と腸 2004; 39: 1375-1386
8) 若村邦彦,工藤進英,竹村織江,他:大腸腺腫・早期癌の内視鏡切除後の follow up.胃と腸 2007; 42: 1453-1457
9) 浦上尚之,五十嵐正広,千野晶子,他:大腸 SM 癌の内視鏡切除後の follow up―サーベイランスに向けて(局所再発,転移再発).胃と腸 2007; 42: 1470-1476
10) 田中信治,五十嵐正広,小林清典,他:大腸 SM 癌内視鏡治療後のサーベイランス.杉原健一・多田正大・藤盛孝博・五十嵐正広編,大腸疾患 NOW 2007,東京,日本 メディカルセンター; 2007: 112-120
11) Japanese Society for Cancer of the Colon and Rectum: Multi-Institutional Registry of Large Bowel Cancer in Japan, Cases treated in 1995-1998. Vol.17(1999), Vol.18 (2000), Vol.21(2001), Vol.24(2003)
12) Heald RJ, Husband EM, Ryall RD: The mesorectum in rectal cancer surgery―the clue to pelvic recurrence? Br J Surg 1982; 69: 613-616
13) MacFarlane JK, Ryall RD, Heald RJ: Mesorectal excision for rectal cancer. Lancet 1993; 341: 457-460
14) Enker WE, Thaler HT, Cranor ML, et al: Total mesorectal excision in the operative treatment of carcinoma of the rectum. J Am Coll Surg 1995; 181: 335-346
15) Lowry AC, Simmang CL, Boulos P, et al: Consensus statement of definitions for anorectal physiology and rectal cancer. Dis Colon Rectum 2001; 44: 915-919
16) Sugihara K, Kobayashi H, Kato T, et al: Indication and benefit of pelvic sidewall dissection for rectal cancer. Dis Colon Rectum 2006; 49: 1663-1672
17) 大腸癌研究会:大腸癌取扱い規約,第6版,東京,金原出版;1998
18) Mentges B, Buess G, Schafer D, et al: Local therapy of rectal tumors. Dis Colon Rectum 1996; 39: 886-892
19) Ono C, Yoshinaga K, Enomoto M, et al: Discontinuous rectal cancer spread in the mesorectum and the optimal distal clearance margin in situ. Dis Colon Rectum 2002; 45: 744-749
20) Santibanes E, Lassalle FB, McCormack L, et al: Simultaneous colorectal and hepatic resections for colorectal cancer: Postoperative and longterm outcomes. J Am Coll Surg 2002; 195: 196-202
21) 望月英隆:腹膜播種を伴う大腸癌.上西紀夫,田中雅夫(編),消化器癌の外科治療,東京,中外医学社;2001: 100-102
22) 岡 正朗,内山哲史,森近博史,他:腹膜播種を伴う大腸癌症例の臨床病理学的検討―肝転移例との比較―.日臨外医会誌 1993; 54: 2535-2539
23) 正木忠彦,武藤徹一郎,安富正幸:大動脈周囲リンパ節の実態―第44回大腸癌研究会アンケート調査報告.日本大腸肛門病会誌 1997; 50: 318-330
24) Murata S, Moriya Y, Akasu T, et al: Resection of both hepatic and pulmonary metastases in patients with colorectal carcinoma. Cancer 1998; 83: 1086-1093
25) Kobayashi K, Kawamura M, Ishihara T: Surgical treatment for both pulmonary and hepatic metastases from colorectal cancer. J Thorac Cardiovasc Surg 1999; 118: 1090-1096
26) Portier G, Elias D, Bouche O, et al: Multicentric randomized trial of adjuvant fluorouracil and folnic acid compared with surgery alone after resection of colorectal liver metastasis: FFCD ACHBTH AURC 9002 Trial. J Clin Oncol 2006; 24: 4976-4982
27) Robinson BJ, Rice TW, Strong SA, et al: Is resection of pulmonary and hepatic metastases warranted in patients with colorectal cancer? J Thorac Cardiovasc Surg 1999; 117: 66-76
28) 森谷冝皓,山口高史,赤須孝之,他:骨盤内局所再発癌に対する積極的外科治療.臨外 2001; 56: 759-765
29) Lambert LA, Colacchio TA, Barth RJ Jr: Interval hepatic resection of colorectal metastases improves patient selection. Arch Surg 2000; 135: 473-479
30) 亀岡信悟,小川真平:治療方針確定のための検査計画.杉原健一(編),再発大腸癌治療ガイドブック,東京,南江堂;2003: 77-83
31) Tschmelitsch J, Kronberger P, Glaser K, et al: Survival after surgical treatment of recurrent carcinoma of the rectum. J Am Coll Surg 1994; 179: 54-58
32) Rodgers MS, McCall JL: Surgery for colorectal liver metastases with hepatic lymphnode involvement: a systematic review. Br J Surg 2000; 87: 1142-1155
33) Martin LW, Warren RS: Current management of colorectal liver metastases. Surg Oncol Clin N Am 2000; 9: 853-876
34) Penna C, Nordlinger B: Colorectal metastasis(liver and lung). Surg Clin N Am 2002; 82: 1075-1090
35) Kato T, Yasui K, Hirai T, et al: Therapeutic results for hepatic metastasis of colorectal cancer with special reference to effectiveness of hepatectomy. Dis Colon Rectum 2003; 46(Suppl): S22-S31
36) Fortner JG, Silva JS, Golbey RB, et al: Multivariate analysis of hepatic metastases from colorectal cancer. I. Treatment by hepatic resection. Ann Surg 1984; 199: 306-316
37) Hughes KS, Simon R, Songhorabodi S, et al: Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of pattern of recurrence. Surgery 1986; 100: 278-284
38) Ekberg H, Tranberg KG, Andersson R, et al: Pattern of recurrence in liver resection for colorectal secondaries. World J Surg 1987; 11: 541-547
39) Nordinger B, Jaeck D, Guiguet M, et al: Surgical resection of hepatic metastases. Multicentric retrospective study by the French Association of Surgery. In: Nordinger B, Jaeck D, editors, Treatment of hepatic metastases of colorectal cancer. Paris Springer-Verlag 1992: 129-146
40) Cady B, Jenkins RL, Steele Jr GD, et al: Surgical margin in hepatic resection for colorectal metastases: a critical and improvable determinant of outcome. Ann Surg 1998; 227: 566-571
41) Yamamoto J, Sugihara K, Kosuge T, et al: Pathologic support for limited hepatectomy in the treatment of liver metastases from colorectal cancer. Ann Surg 1995; 221: 74-78
42) Elias D, Cavalcanti A, Sabourin JC, et al: Results of 136 curative hepatectomies with a safety margin of less than 10 mm for colorectal metastases. J Surg Oncol 1998; 69: 88-93
43) Fong Y, Cohen AM, Fortner JG, et al: Liver resection for colorectal metastases. J Clin Oncol 1997; 15: 938-946
44) Kokudo N, Miki Y, Sugai S, et al: Genetic and histological assessment of surgical margins in resected liver metastases from colorectal carcinoma: minimum surgical margins for successful resection. Arch Surg 2002; 137: 833-840
45) Beckurts KTE, Hoelscher AH, Thorban ST, et al: Significance of lymph node imvolvement at the hepatic hilum in the resection of colorectal liver metastases. Br J Surg 1997; 84: 1081-1084
46) Nakamura S, Suzuki S, Konno H: Resection of hepatic metastases of colorectal carcinoma: 20 years’ experience. J Hepatobiliary Pancreat Surg 1999; 6: 16-22
47) Regnard JF, Grunenwald D, Spaggiari L, et al: Surgical treatment for hepatic and pulmonary metastases from colorectal cancers. Ann Thorac Surg 1998; 66: 214-218
48) Nordlinger B, Vaillant JC, Guiguet M, et al: Survival benefit of repeat liver resections for recurrent colorectal metastases. 143 cases: Association Francaise de Chirurgie. J Clin Oncol 1994; 12: 1491-1496
49) Yamamoto J, Kosuge T, Shimada K, et al: Repeat liver resection for recurrent colorectal liver metastases. Am J Surg 1999; 178: 275-281
50) Petrowsky H, Gonen M, Jarnagin W, et al: Second liver resections are safe and effective treatment for recurrent hepatic metastases from colorectal cancer: a bi-institutional analysis. Ann Surg 2002; 235: 863-871
51) Suzuki S, Sakaguchi T, Yokoi Y, et al: Impact of repeat hepatectomy on recurrent colorectal liver metastases. Surgery 2001; 129: 421-428
52) Nagakura S, Shirai Y, Suda T, et al: Multiple repeat resections of intra and extrahepatic recurrences in patients undergoing initial hepatectomy for colorectal carcinoma metastases. World J Surg 2002; 26: 141-147
53) Tanaka K, Shimada H, Ohta M, et al: Procedures of choice for resection of primary and recurrent liver metastases from colorectal cancer. World J Surg 2004; 28: 482-487
54) Thelen A, Jonas S, Benckert C, et al: Repeat liver resection for recurrent liver metastases from colorectal cancer. Eur J Surg Oncol 2007; 33: 324-328
55) Pessaux P, Lermite E, Brehant O, et al: Repeat hepatectomy for recurrent colorectal liver metastases. J Surg Oncol 2006; 93: 1-7
56) 別府 透,松田貞士,前田健晴,他:転移性肝癌へのマイクロ波凝固療法の応用.外科治療 2000; 83: 237-242
57) Shibata T, Niinobu T, Ogata N, et al: Microwave coagulation therapy for multiple hepatic metastases from colorectal carcinoma. Cancer 2000; 89: 276-284
58) Park IJ, Kim HC, Yu CS, et al: Radiofrequency ablation for metachronous liver metastasis from colorectal cancer after curative surgery. Ann Surg Oncol 2008; 15: 227-232
59) Goya T, Miyazawa N, Kondo H, et al: Surgical resection of pulmonary metastases from colorectal cancer. 10-year follow-up. Cancer 1989; 64: 1418-1421
60) McCormack PM, Burt ME, Bains MS, et al: Lung resection of colorectal metastases. 10-year results. Arch Surg 1992; 127: 1403-1406
61) Ike H, Shimada H, Ohki S, et al: Results of aggressive resection of lung metastases from colorectal carcinoma detected by intensive follow-up. Dis Colon Rectum 2002; 45: 468-475
62) Okumura S, Kondo H, Tsuboi M, et al: Pulmonary resection for metastatic colorectal cancer: experiences with 159 patients. J Thorac Cardiovasc Surg 1996; 112: 867-874
63) McAfee MK, Allen MS, Trastek VF, et al: Colorectal lung metastases: results of surgical excision. Ann Thorac Surg 1992; 53: 780-785
64) 緒方 裕,的野敬子,林 明宏,他:大腸癌肺転移に対する肺切除の遠隔成績.日臨外会誌 2001; 62: 2110-2115
65) 丸田智章,須田武保,畠山勝義,他:大腸癌肺転移に対する肺切除の検討.日消外会誌 2002; 35: 1377-1383
66) Saito Y, Omiya H, Kohno K, et al: Pulmonary metastasectomy for 165 patients with colorectal carcinoma: a prognostic assessment. J Thorac Cardiovasc Surg 2002; 124: 1007-1013
67) 金光幸秀,加藤知行,平井 孝:大腸癌肺転移に対する治療の現況―第55回大腸癌研究会アンケート結果―.日本大腸肛門病会誌 2004; 57: 121-131
68) 斎藤 裕,高田宗尚,矢鋪憲功,他:大腸癌肺転移の手術成績からみた手術適応.北陸外科学会雑誌 2005; 24: 5-8
69) 東山聖彦,高見康二,檜垣直純,他:大腸癌肺転移に対する外科治療―手術適応,工夫と成績について―.臨床消化器内科 2005; 20: 199-206
70) Koga R, Yamamoto J, Saiura A, et al: Surgical resection of pulmonary metastases from colorectal cancer: four favourable prognostic factors. Jpn J Clin Oncol 2006; 36: 643-648
71) Iizasa T, Suzuki M, Yoshida S, et al: Prediction of prognosis and surgical indications for pulmonary metastasectomy from colorectal cancer. Ann Thorac Surg 2006; 82: 254-260
72) Miller G, Biernacki P, Kemeny NE, et al: Outcomes after resection of synchronous or metachronous hepatic and pulmonary colorectal metastases. J Am Coll Surg 2005; 205: 231-238
73) Kandioler D, Krömer E, Tüchler H, et al: Long-term results after repeated surgical removal of pulmonary metastases. Ann Thorac Surg 1998; 65: 909-912
74) Patchell RA, Tibbs PA, Walsh JW, et al: A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 1990; 322: 494-500
75) Wronski M, Arbit E: Resection of brain metastases from colorectal carcinoma in 73 patients. Cancer 1999; 85: 1677-1685
76) D'Andrea G, Isidori A, Caroli E, et al: Single cerebral metastasis from colorectal adenocarcinoma. Neurosurg Rev 2004; 27: 55-57
77) Farnell GF, Buckner JC, Cascino T: Brain metastases from colorectal carcinoma. Cancer 1996; 78: 711-716
78) Borgelt B, Gelber R, Kramer S, et al: The palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 1980; 6: 1-9
79) Kurtz JM, Gelber R, Brady LW, et al: The palliation of brain metastases in a favorable patient population: a randomized clinical trial by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 1981; 7: 891-895
80) Flickinger JC, Kondziolka D, Lunsford LD, et al: A multi-institutional experience with stereotactic radiosurgery for solitary brain metastasis. Int J Radiat Oncol Biol Phys 1994; 28: 797-802
81) Gasper L, ScottC, Rotman M, et al: Recursive partitioning analysis(RPA)of prognostic factors in three Radiation Therapy Oncology Group(RTOG)brain metastases trials. Int J Radiat Oncol Biol Phys 1997; 37: 745-751
82) Andrews DW, Scott CB, Sperduto PW, et al: Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 2004; 363: 1665-1672
83) Aoyama H, Shirato H, Tago M, et al: Stereotactic radiosurgery plus whole-brain radiotherapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA 2006; 295: 2483-2491
84) National Institute of Health Consensus Conference: Adjuvant therapy for patients with colon and rectal cancer. JAMA 1990; 264: 1444-1450
85) Benson AB 3rd, Schrag D, Somerfield MR, et al: American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stageII colon cancer. J Clin Oncol 2004;22: 3408
86) Van Cutsem E, Oliveira J; ESMO Guidelines Working Group: Colon cancer: ESMO clinical recommendations for diagnosis, adjuvant treatment and follow-up. Ann Oncol 2008;19(Supplement 2): ii29-  ii30
87) Haller DG, Catalano PJ, Macdonald JS, et al: PhaseIII study of fluorouracil, leucovorin, and levamisole in high-risk stageII and III colon cancer: final report of Intergroup 0089. J Clin Oncol 2005; 23: 8671-8678
88) André T, Quinaux E, Louvet C, et al: PhaseIII study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stageII and III colon cancer patients: final results of GERCOR C96.1. J Clin Oncol 2007; 25: 3732.
89) Arkenau HT, Reiig K, Porschen R: Adjuvant chemotherapy in curative resected colon carcinoma: 5-fluorouracil/leucovorin versus high-dose 5-fluorouracil 24-h infusion/leucovorin versus high-dose 5-fluorouracil 24-h infusion. Int J Colorectal Dis 2005; 20:258-261
90) Lembersky, BC, Wieand, HS, Petrelli, NJ, et al: Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stageII and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. J Clin Oncol 2006; 24: 2059
91) Twelves C, Wong A, Nowacki MP, et al: Capecitabine as adjuvant treatment for stageIII colon cancer. N Engl J Med 2005; 352: 2696
92) Saltz LB, Niedzwiecki D, Hollis D, et al: Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stageIII colon cancer: results of CALGB 89803. J Clin Oncol 2007; 25: 3456-3461
93) Ychou M, Raoul JL, Douillard JY, et al: A phaseⅢ randomised trial of LV5FU2+irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer(FNCLCC Accord02/FFCD9802). Ann Oncol 2009; 20: 674-680
94) Van Cutsem E, Labianca R, Bodoky G, et al: Randomized phaseIII trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stageIII colon cancer: PETACC-3. J Clin Oncol 2009; 27: 3117-3125
95) André T, Boni C, Mounedji-Boudiaf L, et al; Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer(MOSAIC)Investigators: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350: 2343-2351
96) Kuebler JP, Wieand HS, O'Connell MJ, et al: Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stageII and III colon cancer: results from NSABP C-07. J Clin Oncol 2007; 25: 2198-2204
97) André T, Boni C, Navarro M, et al: Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stageII or III colon cancer in the MOSAIC trial. J Clin Oncol 2009; 27: 3109-3116
98) Wolmark N, Wieand S, Kuebler PJ, et al: A phaseIII trial comparing FULV to FULV+oxaliplatin in stageII or III carcinoma of the colon: Survival results of NSABP Protocol C-07. Proc Am Soc Clin Oncol 2008; 26:(Abstr LBA4005)
99) Haller D, Tabernero J, Maroun, J, et al: First efficacy findings from a randomized phaseIII trial of capecitabine+oxaliplatin vs. bolus 5-FU/LV for stageIII colon cancer(NO16968/XELOXA study). Abstract 5LBA ECCO 15-34th ESMO, 2009
100) Wolmark N, Yothers G, O'Connell MJ, et al: A phaseIII trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stageII or III carcinoma of the colon: Results of NSABP Protocol C-08. Proc Am Soc Clin Oncol 2009; 27: (Abstr LBA4)
101) Alberts SR, Sargent DJ, Smyrk TC, et al: Adjuvant mFOLFOX6 with or without cetuxiumab(Cmab)in KRAS wild-type(WT)patients(pts)with resected stage III colon cancer(CC): Results from NCCTG Intergroup Phase III Trial N0147. Proc Am Soc Clin Oncol 2010; 28: (Abstr CRA3507)
102) Kato T, Ohashi Y, Nakazato H, et al: Efficacy of oral UFT as adjuvant chemotherapy to curative resection of colorectal cancer: multicenter prospective randomized trial. LangenbecksArch Surg 2002; 386: 575-581
103) Akasu T, Moriya Y, Ohashi Y, et al: Adjuvant chemotherapy with uracil-tegafur for pathological stageIII rectal cancer after mesorectal excision with selective lateral pelvic lymphadenectomy: a multicenter randomized controlled trial. Jpn J Clin Oncol 2006; 36:237-244
104) Sakamoto J, Hamada C, Yoshida S, et al: An individual patient data meta-analysis of adjuvant therapy with uracil-tegafur(UFT)in patients with curatively resected rectal cancer. Br J Cancer 2007; 96: 1170-1177
105) Scheithauer W, Rosen H, Kornek GV, et al: Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. Br Med J 1993; 306: 752-755
106) Simmonds PC: Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. Colorectal Cancer Collaborative Group. Br Med J 2000; 321:531-535
107) Cunningham D, Pyrhonen S, James RD, et al: Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998; 352: 1413-1418
108) de Gramont A, Figer A, Seymour M, et al: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18:2938-2947
109) Goldberg R, Sargent D, Morton R, et al: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22: 23-30
110) Saltz LB, Clarke S, Díaz-Rubio E, et al: Bevacizumab in combination with oxaliplatinbased chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phaseIII study. J Clin Oncol 2008; 26: 2013-2019
111) Cassidy J, Clarke S, Díaz-Rubio E, et al: Randomized phaseIII study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 2008; 26: 2006-2012
112) Tournigand C, André T, Achille E, et al: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A Randomized GERCOR Study. J Clin Oncol 2004; 22: 229-237
113) Douillard JY, Cunningham D, Roth AD, et al: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355: 1041-1047
114) Fuchs CS, Marshall J, Mitchell E, et al: Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 2007; 25: 4779-4786
115) Fuchs CS, Marshall J, Barrueco J, et al: Randomized, controlled trial of irinotecan plus infusional, bolus or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study. J Clin Oncol 2008; 26: 689-690
116) Bokemeyer C, Bondarenko I, Makhson A, et al: Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009; 27: 663-671
117) Siena S, Cassidy J, Tabernero J, et al: Randomized phase III study of panitumumab(pmab)with FOLFOX4 compared to FOLFOX4 alone as first-line treatment(tx)for metastatic colorectal cancer(mCRC): PRIME trial. 2010 ASCO Gastrointestinal Cancers Symposium,2010.(Abstr 283)
118) Van Cutsem E, Köhne CH, Hitre E, et al: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360: 1408-1417
119) Kohne C, Mineur L, Greil R, et al: Primary analysis of a phaseII study(20060314)combining first-line panitumumab(pmab)with FOLFIRI in the treatment of patients(pts)with metastatic colorectal cancer(mCRC). 2010 ASCO Gastrointestinal Cancers Symposium, 2010.(Abstr 414)
120) Petrelli N, Herrera L, Rustum Y, et al: A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol 1987;5: 1559-1565
121) 吉野正曠,太田和雄,栗原 稔,他:多施設共同研究による大量 l-leucovorin・5-FU併用療法の進行結腸・直腸癌に対する後期第II相試験(東日本グループ).癌と化学療法 1995; 22: 785-792
122) Hurwitz H, Fehrenbacher L, Hainsworth JD, et al: Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer.J Clin Oncol 2005; 23: 3502-3508
123) Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al: PhaseII, randomized trial comparing Bevacizumab plus fluorouracil(FU)/leucovorin(LV)with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21: 60-65
124) Shirao K, Hoff PM, Ohtsu A, et al: Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur(UFT)plus oral leucovorin(LV)regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV. J Clin Oncol 2004; 22: 3466-3474
125) Sobrero AF, Maurel J, Fehrenbacher L, et al: EPIC: phaseIII trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 2311-2319
126) Peeters M, Price TJ, Hotko YS, et al: Randomized phaseIII study of panitumumab(pmab)with FOLFIRI vs FOLFIRI alone as second-line treatment(tx)in patients(pts)with metastatic colorectal cancer(mCRC): Patient-reported outcomes(PRO). 2010 ASCO Gastrointestinal Cancers Symposium, 2010.(Abstr 282)
127) Rothenberg ML, Oza AM, Bigelow RH, et al: Superiority of oxaliplatin and fluorouracilleucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phaseIII trial. J Clin Oncol 2003; 21: 2059-2069
128) Giantonio BJ, Catalano PJ, Meropol NJ, et al: Bevacizumab in combination with oxaliplatin,fluorouracil, and leucovorin(FOLFOX4)for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007; 25: 1539-1544
129) Rothenberg ML, Cox JV, Butts C, et al: Capecitabine plus oxaliplatin(XELOX)versus 5-fluorouracil/folinic acid plus oxaliplatin(FOLFOX-4)as second-line therapy in metastatic colorectal cancer: a randomized phaseIII noninferiority study. Ann Oncol 2008; 19:1720-1726
130) Cunningham D, Humblet Y, Siena S, et al: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351:337-345
131) Jonker DJ, O'Callaghan CJ, Karapetis CS, et al: Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007; 357: 2040-2048
132) Karapetis CS, Khambata-Ford S, Jonker DJ, et al: K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359: 1757-1765
133) Van Cutsem E, Peeters M, Siena S, et al: Open-label phaseIII trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007; 25: 1658-1664
134) Amado RG, Wolf M, Peeters M, et al: Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 1626-1634
135) Köhne CH, Wils J, Lorenz M, et al: Randomized phaseIII study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European Organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952. J Clin Oncol 2003; 21: 3721-3728
136) Grothey A, Sargent DJ, Goldberg RM, et al: Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004; 22: 1209-1214
137) Douillard JY, Hoff PM, Skillings JR, et al: Multicenter phaseIII study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2002; 20: 3605-3616
138) Carmichael J, Popiela T, Radstone D, et al: Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2002; 20: 3617-3627
139) Grothey A, Sugrue M, Hedrick E, et al: Association between exposure to Bevacizumab (BV)beyond first progression(BBP)and overall survival(OS)in patients(pts)with metastatic colorectal cancer(mCRC): Results from a large observational study (BRiTE). Proc Am Soc Clin Oncol 2007; 25: (Abstr 4036)
140) Punt CJ, Tol J, Rodenburg CJ, et al: Randomized phaseIII study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer(ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group(DCCG). Proc Am Soc Clin Oncol 2008; 26:(Abstr LBA4011)
141) Hecht JR, Mitchell E, Chidiac T, et al: An updated analysis of safety and efficacy of oxaliplatin(Ox)/Bevacizumab(bev)+/- panitumumab(pmab)for first-line treatment(tx)of metastatic colorectal cancer(mCRC)from a randomized, controlled trial(PACCCE).Gastrointestinal Cancers Symposium 2008; (Abstr 273)
142) Meta-Analysis Group in Cancer: Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. J Natl Cancer Inst 1996; 88:252-258
143) Skibber JM, Hoff PM, Minsky BD, et al: Cancer of the Rectum. In: Devita VT, Hellman S, Rosenberg SA(eds). Cancer: Principles and Practice of Oncology(6th ed). Philadelphia, Lippincott, Williams and Wilkins 2001; 1271-1318
144) Swedish Rectal Cancer Trial: Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med 1997; 336: 980-987
145) Camma C, Giunta M, Fiorica F, et al: Preoperative radiotherapy for resectable rectal cancer. A meta-analysis. J Am Med Assoc 2000; 284: 1008-1015
146) Colorectal Cancer Collaborative Group: Adjuvant radiotherapy for rectal cancer: a systematic overview of 22 randomised trials involving 8507 patients. Lancet 2001; 358:1291-1304
147) Kapiteijn E, Marijnen CA, Nagtegaal ID, et al: Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001; 345: 638-646
148) Peeters KC, Marijnen CA, Nagtegaal ID, et al: The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg 2007; 246: 693-701
149) Marijnen CA, van de Velde CJ, Putter H, et al: Impact of short-term preoperative radiotherapy on health-related quality of life and sexual functioning in primary rectal cancer:report of a multicenter randomized trial. J Clin Oncol 2005; 23: 1847-1858
150) Peeters KC, van de Velde CJ, Leer JW, et al: Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients-a Dutch colorectal cancer group study. J Clin Oncol 2005; 23: 6199-6206
151) Francois Y, Nemoz CJ, Baulieux J, et al: Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: The Lyon R90-01 randomized trial. J Clin Oncol 1999; 17: 2396-2402
152) Bosset JF, Collette L, Calais G, et al: EORTC Radiotherapy Group Trial 22921: Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 2006; 355: 1114-1123
153) Gerard JP, Conroy T, Bonnetain F, et al: Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol 2006; 24: 4620-4625
154) Bujko K, Nowacki MP, Nasierowska-Guttmejer A, et al: Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg 2006; 93: 1215-1223
155) Sauer R, Becker H, Hohenberger W, et al; German Rectal Cancer Study Group: Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004;351: 1731-1740
156) Wolmark N, Wieand HS, Hyams DM, et al: Randomized trial of postoperative adjuvantchemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project protocol R-02. J Natl Cancer Inst 2000; 92: 388-396
157) Gervaz PA, Wexner SD, Pemberton JH: Pelvic radiation and anorectal function: introducing the concept of sphincter-preserving radiation therapy. J Am Coll Surg 2002; 195:387-394
158) Temple LK, Wong WD, Minsky B: The impact of radiation on functional outcomes in patients with rectal cancer and sphincter preservation. Semin Radiat Oncol 2003; 13:469-477
159) O'Connell MJ, Martenson JA, Wieand HS, et al: Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med 1994; 331: 502-507
160) Smalley SR, Benedetti JK, Williamson SK, et al: PhaseIII trial of fluorouracil-based chemotherapy regimens plus radiotherapy in postoperative adjuvant rectal cancer: GI INT 0144. J Clin Oncol 2006; 24: 3542-3547
161) Nakfoor BM, Willett CG, Shellito PC, et al: The impact of 5-fluorouracil and intraoperative electron beam radiation therapy on the outcome of patients with locally advanced primary rectal and rectosigmoid cancer. Ann Surg 1998; 228: 194-200
162) Strassmann G, Walter S, Kolotas C, et al: Reconstruction and navigation system for intraoperative brachytherapy using the flab technique for colorectal tumor bed irradiation. Int J Radiat Oncol Biol Phys 2000; 47: 1323-1329
163) Wong CS, Cummings BJ, Brierley JD, et al: Treatment of locally recurrent rectal carcinoma-results and prognostic factors. Int J Radiat Oncol Biol Phys 1998; 40: 427-435
164) Lingareddy V, Ahmad NR, Mohiuddin M: Palliative reirradiation for recurrent rectal cancer. Int J Radiat Oncol Biol Phys 1997; 38: 785-790
165) Bates T: A review of local radiotherapy in the treatment of bone metastases and cord compression. Int J Radiat Oncol Biol Phys 1992; 23: 217-221
166) Nielsen OS, Munro AJ, Tannock IF: Bone metastases: pathophysiology and management policy. J Clin Oncol 1991; 9: 509-524
167) Wu JS, Wong R, Johnston M, et al; Cancer Care Ontario Practice Guidelines Initiative Supportive Care Group: Meta-analysis of dose-fractionation radiotherapy trials for the palliation of painful bone metastases. Int J Radiat Oncol Biol Phys 2003; 55: 594-605
168) Chow E, Harris K, Fan G, et al: Palliative radiotherapy trials for bone metastases: a systematic review. J Clin Oncol 2007; 25: 1423-1436
169) Cancer pain relief and palliative care: Report of a WHO expert committee. WHO Technical Report Series 804. WHO, Geneva, 1990, 21-22
170) 日本緩和医療学会がん疼痛治療ガイドライン作成委員会編:Evidence-Based Medicineに則ったがん疼痛治療ガイドライン.真興交易(株)医書出版部,東京,2000
171) Kathleen M, Foley KM: The treatment of cancer pain. N Engl J Med 1985; 313: 84-95
172) Suzuki K, Dozois RR, Devine RM, et al: Intraoperative irradiation after palliative surgery for locally recurrent rectal cancer. Cancer 1995; 75: 939-952
173) Nymann T, Jess P, Christiansen J: Rate and treatment of pelvic recurrence after abdominoperineal resection and low anterior resection for rectal cancer. Dis Colon Rectum 1995;38: 799-802
174) Tong D, Gillick L, Hendrickson FR: The palliation of symptomatic osseous metastases.Final results of the study by the radiation therapy oncology group. Cancer 1982; 50: 893-899
175) Helyer LK, Law CH, Butler M, et al: Surgery as a bridge to palliative chemotherapy in patients with malignant bowel obstruction from colorectal cancer. Ann Surg Oncol 2007;14: 1264-1271
176) 中田 健,冨田尚裕,岡村 修,他:切除不能進行癌・再発癌に対する緩和的人工肛門造設術の検討.外科治療 2007; 96: 101-105
177) Law WL, Choi HK, Lee YM, et al: Palliation for advanced malignant colorectal obstruction by self-expanding metallic stents; prospective evaluation of outcomes. Dis Colon Rectum 2004; 47, 39-43
178) Khot UP, Lang AW, Murali K, et al: Systemic review of the efficacy and safety of colorectal stents. Br J Surg 2002; 89: 1096-1102
179) Baines M, Oliver DJ, Carter RL, et al: Medical management of intestinal obstruction in patients with advanced malignant disease. A clinical and pathological study. Lancet 2,990-993, 1985
180) Ripamonti C, Twycross R, Baines M, et al: Clinical-practice recommendations for the management of bowel obstruction in patients with end-stage cancer. Support Care Cancer 2001; 9: 223-233
181) Maguire P, Walsh S, Jeacock J, et al: Physical and psychological needs of patients dying from colo-rectal cancer. Palliative Medicine 1999; 13: 45-50
182) Connor SR, Pyenson B, Fitch K, et al: Comparing hospice and nonhospice patient survival among patients who die within a three-year window. J Pain and Symptom Management 2007; 33: 238-246
183) Sprangers MAG, Verde te A, Aaronson NK: The construction and testing of the EORTC Colorectal Cancer-specific Quality of Life Questionnaire Module(QLQ-CR38). Eur J Cancer 1999; 35: 238-247
184) Uki J, Mendoza T, Charles MS, et al: A brief cancer pain assessment tool in Japanese:The utility of the Japanese Brief Pain Inventory-BPI-J. J Pain Symptom Manage 1998;16: 364-373
185) Renehan AG, Egger M, Saunders MP, et al: Impact on survival of intensive follow up after curative resection for colorectal cancer: systematic review and meta-analysis of randomised trial. Br Med J 2002; 324: 813-816.
186) Figueredo A, Rumble RB, Maroun J, et al: Follow-up of patients with curatively resected colorectal cancer: a practice guideline. BMC Cancer 2003; 6: 26
187) Renehan AG, Egger M, Saunders MP, et al: Mechanisms of improved survival from intensive followup in colorectal cancer: a hypothesis. Br J Cancer 2005; 92: 430-433
188) Jeffery M, Hickey BE, Hider PN: Follow-up strategies for patients treated for non-metastatic colorectal cancer. Cochrane Database Syst Rev 2007; 24: CD002200
189) Tjandra JJ, Chan MK: Follow-up after curative resection of colorectal cancer: a metaanalysis.Dis Colon Rectum 2007; 50: 1783-1799
190) Bruinvels D, Stiggelbout A, Kievit J, et al: Follow-up of patients with colorectal cancer.A meta-analysis. Ann Surg 1994; 219: 174-182
191) Fleischer D, Goldberg S, Browning T, et al: Detection and surveillance of colorectal cancer. JAMA 1989; 261: 580-585
192) ESMO Guidelines Working Group: Colon cancer: ESMO clinical recommendations for diagnosis, adjuvant treatment and follow-up. Ann Oncol 2007; 18(Suppl 2):ii21-ii22
193) 渡辺 正,豊田美知子,伊藤勝基,他:直腸癌局所再発診断における経時的骨盤部CT撮影の意義.日本大腸肛門病会誌 1989; 42: 1031-1038
194) Ramirez JM, Mortensen NJM, Takeuchi N, et al: Endoluminal ultrasonography in the follow-up of patients with rectal cancer. Br J Surg 1994; 81: 692-694
195) Löhnert MSS, Doniec JM, Henne-Bruns D: Effectiveness of endoluminal sonography in the identification of occult local rectal cancer recurrences. Dis Colon Rectum 2000; 43:483-491
196) Moore HG, Akhurst T, Larson SM, et al: A case-controlled study of 18-fluorodeoxyglucose positron emission tomography in the detection of pelvic recurrence in previously irradiated rectal cancer patients. J Am Coll Surg 2003; 197: 22-28
197) Flanagan FL, Dehdashti F, Ogunbiyi OA, et al: Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer. Ann Surg 1998;227: 319-323
198) Winawer S, Fletcher R, Rex D, et al: Colorectal cancer screening and surveillance: clinical guidelines and rationale-update based on new evidence. Gastroeterology 2003; 124:544-560
199) Desch CE, BensonIII AB, Somerfield MR, et al: Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology Practice Guideline. J Clin Oncol 2005; 23: 8512-8519
200) Rex DK, Kahi CJ, Levin B, et al: Guidelines for colonoscopy surveillance after cancer resection: a consensus update by the American Cancer Society and the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology 2006; 130: 1865-1871
201) National Comprehensive Cancer Network: NCCN clinical practice guideline in oncology.Colon cancer-v.1.2008. http://www.nccn.org/professionals/physician_gls/PDF/colon.pdf(accessed 28 March 2008)
202) Metcalfe MS, Mullin EJ, Maddern GJ: Choice of surveillance after hepatectomy for colorectal metastases. Arch Surg 2004; 139: 749-754
203) Green RJ, Metlay JP, Propert K, et al: Surveillance for second primary colorectal cancer after adjuvant chemotherapy: an analysis of Intergroup 0089. Ann Int Med 2002; 136:261-269
204) 石黒めぐみ,望月英隆,杉原健一,他:大腸癌に合併する多発癌・重複がんに関するフォローアップについて.日本大腸肛門病会誌 2006; 59: 863-868
205) Berman J, Cheung R, Weiberg D: Surveillance after colorectal cancer resection. Lancet 2000; 355: 395-399
206) Ueno H, Mochizuki H, Hashiguchi Y, et al: Risk factors for an adverse outcome in early invasive colorectal carcinoma. Gastroenterology 2004; 127: 385-394
207) Kitajima K, Fujimori T, Fujii S, et al: Correlations between lymph node metastasis and depth of submucosal invasion in submucosal invasive colorectal carcinoma: a Japanese collaborative study. J Gastroenterol 2004; 39: 534-543
208) 武田 純,長廻 紘,奥山 隆,他:5.大腸sm癌の取り扱い.b.内視鏡治療後の追加手術が必要な条件.武藤徹一郎(監),渡辺英伸,杉原健一,多田正大(編),大腸疾患 NOW 2004,日本メディカルセンター,東京,2004: 60-69
209) Tanaka S, Haruma K, Oh-e H, et al: Conditions of curability after endoscopic resection for colorectal carcinoma with submucosally massive invasion. Oncol Rep 2000; 7: 783-788
210) 大腸癌研究会編:大腸癌取扱い規約,第2版,金原出版,東京,1980
211) 大腸癌研究会編:大腸癌取扱い規約,第5版,金原出版,東京,1994
212) 大腸癌研究会編:大腸癌治療ガイドライン-医師用2005年版,金原出版,東京,2005
213) 今井 環:人体癌腫発育状況の形態学的考察.福岡医誌 1954; 45: 72-102
214) 河内 洋,小池盛雄.大腸癌における簇出診断の意義(2)大腸癌研究会簇出検討プロジェクトの結果.武藤徹一郎(監),杉原健一,多田正大,藤盛孝博,五十嵐正広(編),大腸疾患 NOW 2007,日本メディカルセンター,東京,2007: 87-92
215) Lacy AM, Garcia-Valdecasas JC, Delgado S, et al. Laparoscopy-assisted colectomy versus open colectomy for treatment of non-metastatic colon cancer: a randomised trial.Lancet 2002; 359: 2224-2229
216) Weeks JC, Nelson H, Gelber S, et al; Clinical Outcomes of Surgical Therapy(COST)Study Group: Short-term quality-of-life outcomes following laparoscopic-assisted colectomy vs open colectomy for colon cancer: a randomized trial. JAMA 2002; 287: 321-328
217) Clinical Outcomes of Surgical Therapy Study Group: A comparison of laparoscopically assisted and open colectomy for colon cancer. N Engl J Med 2004; 350: 2050-2059
218) Veldkamp R, Kuhry E, Hop WC, et al; Colon Cancer Laparoscopic or Open Resection Study Group: Laparoscopic surgery versus open surgery for colon cancer; short-term outcomes of a randomised trial. Lancet Oncol 2005; 6: 477-484
219) Leung KL, Kwok SP, Lam SC, et al: Laparoscopic resection of rectosigmoid carcinoma:prospective randomised trial. Lancet 2004; 363: 1187-1192.
220) Schwenk W, Haase O, Neudecker J, et al: Short term benefits for laparoscopic colorectal resection. Cochrane Database Syst Rev 2005; 20: CD003145. Review
221) Guillou PJ, Quirke P, Thorpe H, et al; MRC CLASICC trial group: Short-term endpoints of conventional versus laparoscopic-assisted surgery in patients with colorectal cancer (MRC CLASICC trial): multicentre, randomised controlled trial. Lancet 2005; 365:1718-1726
222) Schlachta CM, Mamazza J, Poulin EC. Are transverse colon cancers suitable for laparoscopic resection? Surg Endosc 2007; 21: 396-399
223) Senagore AJ, Delaney CP, Madboulay K, et al: Laparoscopic colectomy in obese and nonobese patients. J Gastrointest Surg 2003; 7: 558-561
224) Lascano CA, Kaidar-Person O, Szomstein S, et al: Challenges of laparoscopic colectomy in the obese patient: a review. Am J Surg 2006; 192: 357-365
225) Arteaga González I, Martín Malagón A, López-Tomassetti Fernández EM, et al: Impact of previous abdominal surgery on colorectal laparoscopy results: a comparative clinical study. Surg Laparosc Endosc Percutan Tech 2006; 16: 8-11
226) Kitano S, Inomata M, Sato A, et al: Randomized controlled trial to evaluate laparoscopic surgery for colorectal cancer: Japan Clinical Oncology Group Study JCOG 0404. Jpn J Clin Oncol 2005; 35: 475-477
227) Jayne DG, Guillou PJ, Thorpe H, et al: Randomized trial of laparoscopic-assisted resection of colorectal carcinoma: 3-year results of the UK MRC CLASICC Trial Group. J Clin Oncol. 2007; 25: 3061-3068
228) National Comprehensive Cancer Network: NCCN clinical practice guideline in oncology.Rectal cancer-v.1.2008. http://www.nccn.org/professionals/physician_gls/PDF/rectal.pdf(accessed 28 March 2008)
229) Cummins ER, Kenneth DV, Poole GV: Incurable colorectal carcinoma: The role of surgical palliation. Am Surgeon 2004; 70: 433-437
230) Law WL, Chan WF, Lee YM, et al: Non-curative surgery for colorectal cancer: critical appraisal of outcomes. Int J Colorectal Dis 2004; 19: 197-202
231) Konyalian VR, Rosing DK, Haukoos JS, et al: The role of primary tumour resection in patients with stage IV colorectal cancer. Colorectal Dis 2007; 9: 430-437
232) Sarela AI, Guthrie JA, Seymour MT, et al: Non-operative management of the primary tumour in patients with incurable stage IV colorectal cancer. Br J Surg 2001; 88: 1352-1356
233) Muratore A, Zorzi D, Bouzari H, et al: Asymptomatic colorectal cancer with un-resectable liver metastasis: Immediate colorectal resection or up-front systemic chemotherapy? Ann Surg Oncol 2006; 14: 766-770
234) Mentha G, Majno PE, Andres A, et al: Neoadjuvant chemotherapy and resection of advanced synchronous liver metastasis before treatment of the colorectal primary. Br J Surg 2006; 93: 872-878
235) Karoui M, Charachon A, Delbaldo C, et al: Stents for palliation of obstructive metastatic colon cancer. Impact on management and chemotherapy administration. Arch Surg 2007;142: 619-623
236) Rosen SA, Buell JF, Yoshida A, et al: Initial presentation with stage IV colorectal cancer.How aggressive should we be? Arch Surg 2000; 135: 530-535
237) Pestieau SR, Sugarbaker PH: Treatment of primary colon cancer with peritoneal carcinomatosis comparison of concomitant vs. delayed management. Dis Colon Rectum 2000;43: 1341-1348
238) Sugarbaker PH: Peritonectomy procedures. Ann Surg 1995; 221: 29-42
239) Verwaal VJ, Ruth S, Witkamp A, et al: Long-term survival of peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol 2005; 12: 65-71
240) Yan TD, Black D, Savady R, et al: Systemic review on the efficacy of cytoreductive surgery combined with perioperayive intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma. J Clin Oncol 2006; 24: 4011-4019
241) Bijelic L, Yan TD, Sugarbaker PH: Failure analysis of recurrent disease following complete cytoreduction and perioperative intraperitoneal chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer. Ann Surg Oncol 2007; 14: 2281-2288
242) Verwaal VJ, Ruth S, Bree E, et al: Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative in patients with peritoneal carcinomaosis of colorectal cancer. J Clin Oncol 2003; 21: 3737-3743
243) Esquivel J, Sticca R, Sugarbaker P, et al: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Ann Surg Oncol 2007; 14: 128-133
244) Levine EA, Ronnett BM, Mansfield PF, et al: Overview of cytoreductive surgery and intraperitoneal hyperthermic chemotherapy for peritoneal dissemination of appendiceal and colorectal neoplasms. ASCO 2008 Educational Book, 2008, 153-159
245) Wanebo HJ, Koness RJ, Vezeridis MP, et al: Pelvic resection of recurrent rectal cancer.Ann Surg 1994; 220: 586-595; discussion 595-597
246) Ogunbiyi OA, McKenna K, Birnbaum EH, et al: Aggressive surgical management of recurrent rectal cancer--is it worthwhile? Dis Colon Rectum 1997; 40: 150-155
247) Moriya Y, Akasu T, Fujita S, et al: Total pelvic exenteration with distal sacrectomy for fixed recurrent rectal cancer in the pelvis. Dis Colon Rectum 2004; 47: 2047-2053
248) Hartley JE, Lopez RA, Paty PB, et al: Resection of locally recurrent colorectal cancer in the presence of distant metastases: can it be justified? Ann Surg Oncol 2003; 10: 227-233
249) Temple WJ, Saettler EB: Locally recurrent rectal cancer: role of composite resection of extensive pelvic tumors with strategies for minimizing risk of recurrence. J Surg Oncol 2000; 73: 47-58
250) Henry LR, Sigurdson E, Ross EA, et al: Resection of isolated pelvic recurrences after colorectal surgery: long-term results and predictors of improved clinical outcome. Ann Surg Oncol 2007; 14: 1081-1091
251) Rodriguez-Bigas MA, Herrera L, Petrelli NJ: Surgery for recurrent rectal adenocarcinoma in the presence of hydronephrosis. Am J Surg 1992; 164: 18-21
252) Larsen SG, Wiig JN, Giercksky KE: Hydronephrosis as a prognostic factor in pelvic recurrence from rectal and colon carcinomas. Am J Surg 2005; 190: 55-60
253) Vermaas M, Ferenschild FT, Nuyttens JJ, et al: Preoperative radiotherapy improves outcome in recurrent rectal cancer. Dis Colon Rectum 2005; 48: 918-928
254) Saito N, Koda K, Takiguchi N, et al: Curative surgery for local pelvic recurrence of rectal cancer. Dig Surg 2003; 20: 192-199
255) Lowy AM, Rich TA, Skibber JM, et al: Preoperative infusional chemoradiation, selective intraoperative radiation, and resection for locally advanced pelvic recurrence of colorectal adenocarcinoma. Ann Surg 1996; 223: 177-185
256) Valentini V, Morganti AG, De Franco A, et al: Chemoradiation with or without intraoperative radiation therapy in patients with locally recurrent rectal carcinoma: prognostic factors and long term outcome. Cancer 1999; 86: 2612-24
257) Wiggers T, de Vries MR, Veeze-Kuypers B: Surgery for local recurrence of rectal carcinoma. DCR 1996 Surgery for local recurrence of rectal carcinoma. Dis Colon Rectum 1996; 39: 323-328
258) Haddock MG, Gunderson LL, Nelson H, et al: Intraoperative irradiation for locally recurrent colorectal cancer in previously irradiated patients. Int J Radiat Oncol Biol Phys 2001; 49: 1267-1274
259) Mohiuddin M, Marks G, Marks J: Long-term results of reirradiation for patients with recurrent rectal carcinoma Cancer 2002; 95: 1144-1150
260) Shoup M, Guillem JG, Alektiar KM, et al: Predictors of survival in recurrent rectal cancer after resection and intraoperative radiotherapy. Dis Colon Rectum 2002; 45: 585-592
261) Ambiru S, Miyazaki M, Ito H, et al: Resection of hepatic and pulmonary metastases in patients with colorectal carcinoma. Cancer 1998; 82: 274-278
262) Shah SA, Haddad R, Al-Sukhni W, et al: Surgical resection of hepatic and pulmonary metastases from colorectal carcinoma. J Am Coll Surg 2006; 202: 468-475
263) Nagakura S, Shirai Y, Yamato Y, et al: Simultaneous detection of colorectal carcinoma liver and lung metastases does not warrant resection. J Am Coll Surg 2001; 193: 153-160
264) Mineo TC, Ambrogi V, Tonini G, et al: Longterm results after resection of simultaneous and sequential lung and liver metastases from colorectal carcinoma. J Am Coll Surg 2003; 197: 386-391
265) Lorenz M, Müller HH, Schramm H, et al: Randomized trial of surgery versus surgery followed by adjuvant hepatic arterial infusion with 5-fluorouracil and folinic acid for liver metastases of colorectal cancer. German Cooperative on Liver Metastases(Arbeitsgruppe Lebermetastasen). Ann Surg 1998; 228: 756-762
266) Kemeny MM, Adak S, Gray B, et al: Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy-an intergroup study. J Clin Oncol 2002; 20: 1499-1505
267) Lygidakis NJ, Ziras N, Parissis J: Resection versus resection combined with adjuvant pre- and post-operative chemotherapy-immunotherapy for metastatic colorectal liver cancer. A new look at an old problem. Hepatogastroenterology 1995; 42: 155-161
268) Lygidakis NJ, Sgourakis G, Vlachos L, et al: Metastatic liver disease of colorectal origin:The value of locoregional immunochemotherapy combined with systemic chemotherapy following liver resection: Results of a prospective randomized study. Hepatogastroenterology 2001; 48: 1685-1691
269) Asahara T, Kikkawa M, Okajima M, et al: Studies of postoperative transarterial infusion chemotherapy for liver metastasis of colorectal carcinoma after hepatectomy. Hepatogastroenterology 1998; 45: 805-811
270) Rudroff C, Altendorf-Hoffmann A, Stangl R, et al: Prospective randomised trial on adjuvant hepatic-artery infusion chemotherapy after R0 resection of colorectal liver metastases. Langenbecks Arch Surg 1999; 384: 243-249
271) Kemeny NE, Gonen M: Hepatic arterial infusion after liver resection. N Engl J Med 2005; 352: 734-735
272) Tono T, Hasuike Y, Ohzato H, et al: Limited but definite efficacy of prophylactic hepatic arterial infusion chemotherapy after curative resection of colorectal liver metastases: A randomized study. Cancer 2000; 88: 1549-1556
273) Ychou M, Hohenberger W, Thezenas S, et al: A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer. Ann Oncol 2009; 20: 1964-1970
274) Adam R, Pascal G, Castaing D, et al: Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases? Ann Surg 2004; 240:1052-1061; discussion 1061-1064
275) Tanaka K, Adam R, Shimada H, et al: Role of neoadjuvant chemotherapy in the treatment of multiple colorectal metastases to the liver. Br J Surg 2003; 90: 963-969
276) Nordlinger B, Sorbye H, Glimelius B, et al; EORTC Gastro-Intestinal Tract Cancer Group; Cancer Research UK; Arbeitsgruppe Lebermetastasen und-tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie(ALM-CAO); Australasian Gastro-Intestinal Trials Group(AGITG); Fédération Francophone de Cancérologie Digestive(FFCD). Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer(EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008; 22; 371: 1007-1016
277) Bilchik AJ, Poston G, Curley SA, et al: Neoadjuvant chemotherapy for metastatic colon cancer: a cautionary note. J Clin Oncol 2005; 23: 9073-9078
278) Vauthey JN, Pawlik TM, Ribero D, et al: Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for colorectal metastases. J Clin Oncol 2006; 24: 2065-2071
279) Delaunoit T, Alberts SR, Sargent DJ, et al: Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741. Ann Oncol 2005; 16: 425-429
280) Adam R: Developing strategies for liver metastases from colorectal cancer. Semin Oncol 2007; 34(2 Suppl 1): S7-11
281) Bismuth H, Adam R, Lévi F, et al: Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 1996; 224: 509-520
282) Adam R, Delvart V, Pascal G, et al: Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 2004; 240: 644-657
283) Kemeny NE, Niedzwiecki D, Hollis DR, et al: Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers(CALGB 9481). J Clin Oncol 2006; 24: 1395-1403
284) Mocellin S, Pilati P, Lise M, et al: Meta-analysis of hepatic arterial infusion for unresectable liver metastases from colorectal cancer: the end of an era? J Clin Oncol 2007;25: 5649-5654
285) Kemeny N, Jarnagin W, Paty P, et al: PhaseⅠ trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer. J Clin Oncol 2005; 23: 4888-4896
286) Sargent DJ, Goldberg RM, Jacobson SD, et al: A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 2001; 345: 1091-1097
287) Sundararajan V, Mitra N, Jacobson JS, et al: Survival associated with 5-fluorouracilbased adjuvant chemotherapy among elderly patients with node-positive colon cancer.Ann Intern Med 2002; 136: 349-357
288) Jessup JM, Stewart A, Greene FL, et al: Adjuvant chemotherapy for stageIII colon cancer: implications of race/ethnicity, age, and differentiation. JAMA 2005; 294: 2703-2711
289) QUASAR Collaborative Group, Gray R, Barnwell J, et al: Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 2007; 370:2020-2029
290) Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials(IMPACT)investigators. Lancet 1995; 345: 939-944
291) Gill S, Loprinzi CL, Sargent DJ, et al: Pooled analysis of fluorouracil-based adjuvant therapy for stageII and III colon cancer: who benefits and by how much? J Clin Oncol 2004;22: 1797-1806
292) Figueredo A, Charette ML, Maroun J, et al: Adjuvant therapy for stageII colon cancer:a systematic review from the Cancer Care Ontario Program in evidence-based care's gastrointestinal cancer disease site group. J Clin Oncol 2004; 22: 3395-3407
293) Schrag D, Rifas-Shiman S, Saltz L, et al: Adjuvant chemotherapy use for Medicare beneficiaries with stageII colon cancer. J Clin Oncol 2002; 20: 3999-4005
294) O'Connell MJ, Laurie JA, Kahn M, et al: Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol 1998; 16:295-300
295) Chau I, Norman AR, Cunningham D, et al: A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer. Ann Oncol 2005; 16: 549-557
296) Chen HX, Mooney M, Boron M, et al: PhaseII multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301. J Clin Oncol 2006; 24: 3354-3360
297) Reidy DL, Chung KY, Timoney JP, et al: Bevacizumab 5mg/kg can be infused safely over 10minutes, J Clin Oncol 2007; 25: 2691-2695
298) Cappuzzo F, Finocchiaro G, Rossi E, et al: EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients. Ann Oncol 2008; 19:717-723
299) Lièvre A, Bachet JB, Boige V, et al: KRAS mutation as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008;26: 374-379
300) Lièvre A, Bachet JB, Corre DL, et al: KRAS mutation status is predictive of response to Cetuximab therapy in colorectal cancer. Cancer Res 2006; 66: 3992-3995
301) Khambata-Ford S, Garrett CR, Meropol NJ, et al: Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007; 25: 3230-3237
302) de Reynies A, Boige V, Milano G, et al: KRAS mutation signature in colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer 2007; 96: 1166-1169
303) Di Fiore F, Blanchard F, Charbonnier F, et al: Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer 2007; 96: 1166-1169
304) Wierzbicki R, Jonker DJ, Moore MJ, et al: A phaseII, multicenter study of cetuximab monotherapy in patients with refractory, metastatic colorectal carcinoma with absent epidermal growth factor receptor immunostaining. Invest New Drugs 2009; 23: 1803-1810
305) Nagawa H, Muto T, Sunouchi K, et al: Randomized, controlled trial of lateral node dissection vs. nerve-preserving resection in patients with rectal cancer after preoperative radiotherapy. Dis Colon Rectum 2001; 44: 1274-1280
306) Kim JS, Kim JS, Cho MJ, et al: Preoperative chemoradiation using oral capecitabine in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2002; 54: 403-408
307) Rodel C, Grabenbauer GG, Papadopoulos T, et al: PhaseI/II trial of capecitabine, oxaliplatin,and radiation for rectal cancer. J Clin Oncol 2003; 21: 3098-3104
308) Mohiuddin M, Winter K, Mitchell E, et al: Randomized phaseII study of neoadjuvant combined-modality chemoradiation for distal rectal cancer: Radiation Therapy Oncology Group Trial 0012. J Clin Oncol 2006; 24: 650-655
309) Cancer and Leukemia Group B 89901, Ryan DP, Niedzwiecki D, et al: PhaseI/II study of preoperative oxaliplatin, fluorouracil, and external-beam radiation therapy in patients with locally advanced rectal cancer: Cancer and Leukemia Group B 89901. J Clin Oncol 2006; 24: 2557-2562
310) Sato T, Kokuba Y, Koizumi W, et al: PhaseⅠ trial of neoadjuvant preoperative chemotherapy with S-1 and irinotecan plus radiation in patients with locally advanced rectal cancer.Int J Radiat Oncol Biol Phys 2007; 69: 1442-1447
311) Wong SJ, Winter K, Meropol NJ, et al: RTOG 0247: A randomized phaseII study of neoadjuvant capecitabine and irinotecan versus capecitabine and oxaliplatin with concurrent radiation therapy for locally advanced rectal cancer. Proc Am Soc Clin Oncol 2008;26:(Abstr 4021)
312) De Paoli A, Chiara S, Luppi G, et al: Capecitabine in combination with preoperative radiation therapy in locally advanced, resectable, rectal cancer: a multicentric phaseII study.Ann Oncol 2006; 17: 246-251
313) Aschele C, Friso ML, Pucciarelli S, et al: A phaseI-II study of weekly oxaliplatin, 5-fluorouracil continuous infusion and preoperative radiotherapy in locally advanced rectal cancer. Ann Oncol 2005; 16: 1140-1146
314) Mehta VK, Cho C, Ford JM, et al: PhaseII trial of preoperative 3D conformal radiotherapy,protracted venous infusion 5-fluoouracil, and weekly CPT-11, followed by surgery for ultrasound-staged T3 rectal cancer. Int J Radiat Oncol Biol Phys 2003; 55: 132-137
315) Gunderson LL, Nelson H, Martenson JA, et al: Locally advanced primary colorectal cancer: intraoperative electron and external beam irradiation+/- 5-FU. Int J Radiat Oncol Biol Phys 1997; 37: 601-614
316) Freedman GM, Meropol NJ, Sigurdson ER, et al: PhaseⅠ trial of preoperative hypofractionated intensity-modulated radiotherapy with incorporated boost and oral capecitabine in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2007; 67: 1389-1393
317) Tsujii H, Mizoe JE, Kamada T, et al: Overview of clinical experiences on carbon ion radiotherapy at NIRS. Radiother Oncol. 2004; 73 Suppl 2: S41-49
318) Ohlsson B, Breland U, Ekberg H, et al: Follow-up after curative surgery for colorectal carcinoma. Randomized comparison with no follow-up. Dis Colon Rectum 1995; 38: 619-626
319) Mäkelä JT, Laitinen SO, Kairaluoma MI: Five-year follow-up after radical surgery for colorectal cancer. Arch Surg 1995; 130: 1062-1067
320) Kjeldsen BJ, Kronborg O, Fenger C, et al: A prospective randomized study of follow-up after radial surgery for colorectal cancer. Br J Surg 1997; 84: 666-669
321) Pietra N, Sarli L, Costi R, et al: Role of follow-up in management of local recurrences of colorectal cancer. A prospective, randomized study. Dis Colon Rectum 1998; 41: 1127-1133
322) Schoemaker D, Black R, Giles L, et al: Yearly colonoscopy, liver CT, and chest radiography do not influence 5-year survival of colorectal cancer patients. Gastroenterology 1998; 114: 7-14
323) Secco GB, Fardelli R, Gianquinto D, et al: Efficacy and cost of risk-adopted follow-up in patients after colorectal cancer surgery: a prospective, randomized and controlled trial.Eur J Surg Oncol 2002; 28: 418-423
324) Grossmann EM, Johnson FE, Virgo KS, et al: Follow-up of colorectal cancer patients after resection with curative intent―the GILDA trial. Surg Oncol 2004; 13: 119-124
325) Rodriguez-Moranta F, Salo J, Arcusa A, et al: Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized,controlled trial. J Clin Oncol 2006; 24: 386-393
326) Wattchow DA, Weller DP, Esterman A, et al: General practice vs surgical-based followup for patients with colon cancer: randomised controlled trial. Br J Cancer 2006; 24:1116-1121
327) Rosen M, Chan L, Beart RW, et al: Follow-up of colorectal cancer. A meta analysis. Dis Colon Rectum 1998; 41: 1116-1126
328) 甲斐俊吉,小泉浩一,今里 真,他:大腸癌切除後の異時性重複癌について―大腸と他臓器との重複癌の検討―.外科 1995; 57: 1300-1305
329) 万井真理子,吉川宣輝,西庄 勇,他:大腸重複癌の臨床病理学的検討.日本大腸肛門病会誌 2000; 53: 540-546
330) 塩澤 学,土田知史,菅野伸洋,他:大腸癌における多臓器重複癌の検討.日消外会誌 2007; 40: 1557-1564
331) Tanaka H, Hiyama T, Hanai A, et al: Second primary cancers following colon and rectal cancer in Osaka, Japan. Jpn J Cancer Res 1991; 82: 1356-1365
332) 寺本龍生,渡邊昌彦,北島政樹:大腸癌二次発癌のサーベイランスと対策.消化器癌1997; 7: 169-172
333) Ueno M, Muto T, Oya M, et al: Multiple primary cancer: an experience at the Cancer Institute Hospital with special reference to colorectal cancer. Int J Clin Oncol 2003; 8:162-167
334) Yamamoto S, Yoshimura K, Ri S, et al: The risk of multiple primary malignancies with colorectal carcinoma. Dis Colon Rectum 2006; 49: S30-S36
335) Lynge E, Jensen OM, Carstensen B: Second cancer following cancer of the digestive system in Denmark, 1943-80. Natl Cancer Inst Monogr 1985; 68: 277-308
336) Buiatti E, Crocetti E, Acciai A, et al: Incidence of second primary cancers in three Italian population-based cancer registries. Eur J Cancer 1997; 33: 1829-1834
337) Evans H, Møller H, Robinson D, et al: The risk of subsequent primary cancers after colorectal cancer in southeast England. Gut 2002; 50: 647-652
338) Hoar SK, Wilson J, Blot WJ, et al: Second cancer following cancer of the digestive system in Connecticut, 1935-82. Natl Cancer Inst Monogr 1985; 68: 49-82
339) McCredie M, Macfarlane GJ, Bell J, et al: Second primary cancers after cancers of the colon and rectum in New South Wales, Australia, 1972-1991. Cancer Epidemiol Biomarkers Prev 1997; 6: 155-160
340) Armed F, Goodman MT, Kosary C, et al: Excess risk of subsequent primary cancers among colorectal carcinoma survivors, 1975-2001. Cancer 2006; 107: 1162-1171
341) 島谷英彦,藤井久男,小山文一,他:大腸他臓器重複癌症例の検討.日本大腸肛門病会誌 2003; 56: 294-298


<前へ 次へ>
書誌情報